X
[{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and FUJI YAKUHIN Conclude License Agreement","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Fuji Yakuhin"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion\u2122 Targeting Severe Osteoarthritis of the Knee (OAK)","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ampio Pharmaceuticals"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TLC BioSciences"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Paradigm Biopharmaceuticals"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$30.0 million","newsHeadline":"Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gr\u00fcnenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Grunenthal"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$95.5 million","upfrontCash":"$10.0 million","newsHeadline":"Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LG Chem"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart\u00ae","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ocugen"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500 Million","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Grunenthal"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Selecta Biosciences"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$705.0 million","upfrontCash":"$75.0 million","newsHeadline":"Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Selecta Biosciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.
Lead Product(s):
Pegadricase ,ImmTOR
Therapeutic Area: Rheumatology
Product Name: SEL-212
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Swedish Orphan Biovitrum AB
Deal Size: $705.0 million
Upfront Cash: $75.0 million
Deal Type: Licensing Agreement
October 31, 2023
Details:
SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint deformity.
Lead Product(s):
SEL-037,SEL-110
Therapeutic Area: Rheumatology
Product Name: SEL-212
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 21, 2023
Details:
Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.
Lead Product(s):
Autologous Cartilagenous Tissue
Therapeutic Area: Rheumatology
Product Name: NeoCart
Highest Development Status: Phase III
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 16, 2022
Details:
LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Lead Product(s):
Tigulixostat
Therapeutic Area: Rheumatology
Product Name: LC350189
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Innovent Biologics
Deal Size: $95.5 million
Upfront Cash: $10.0 million
Deal Type: Collaboration
December 14, 2022
Details:
RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.
Lead Product(s):
Resiniferatoxin
Therapeutic Area: Rheumatology
Product Name: RTX
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 18, 2022
Details:
The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.
Lead Product(s):
Resiniferatoxin
Therapeutic Area: Rheumatology
Product Name: RTX
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shionogi
Deal Size: $670.0 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
August 04, 2022
Details:
Under the terms of the agreement, TLC will primarily be responsible for the development of the product TLC599 (Dexamethasone Sodium Phosphate) and EVL will primarily be responsible for obtaining regulatory approval and commercialization of the product in the United States.
Lead Product(s):
Dexamethasone Sodium Phosphate
Therapeutic Area: Rheumatology
Product Name: TLC599
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Endo International
Deal Size: $140.0 million
Upfront Cash: $30.0 million
Deal Type: Agreement
June 13, 2022
Details:
The purpose of the study is to measure the change in pain and function with subcutaneous injections of Zilosul (Pentosan Polysulfate Sodium) compared with subcutaneous injections of placebo in participants with kOA pain.
Lead Product(s):
Pentosan Polysulfate Sodium
Therapeutic Area: Rheumatology
Product Name: Zilosul
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 17, 2022
Details:
Results showed that TLC599 (Dexamethasone Sodium Phosphate), a proprietary BioSeizer, demonstrated statistically significantly greater reduction in WOMAC pain and function as well as VAS scores compared to placebo through 24 weeks.
Lead Product(s):
Dexamethasone Sodium Phosphate
Therapeutic Area: Rheumatology
Product Name: TLC599
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 07, 2022
Details:
Ampion, a novel biologic drug containing a blood-derived cyclized peptide, demonstrated a statistically significant reduction in pain and trended favorably toward improvement in function versus saline control, retained more than 85% power to evaluate improvements in pain.
Lead Product(s):
Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Rheumatology
Product Name: Ampion
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 02, 2022